Home  »  Stocks to Invest   »  ObsEva SA (OBSV) Stock Inclining in the Regular Tr...

ObsEva SA (OBSV) Stock Inclining in the Regular Trading, Here’s why.

ObsEva SA (OBSV) is one of the leading innovative biopharmaceutical company engaged in the development and commercialization of innovative treatments to improve women’s reproductive health and pregnancy. The company mostly focuses on the cure of uterine fibroids, endometriosis, and preterm labor. One of the main candidate products of the company is Linzagolix associated with the treatment of pain in pre-menopausal women. Another lead product is Ebopiprant used for the treatment of preterm labor.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


The price of OBSV stock during the regular trading on January 3, 2022, was last checked to be $2.08 with a leap of 4.27%.

OBSV: Events and Happenings

On January 3, 2022, OBSV reported that the company’s executives will present the company and give corporate update at the approaching H.C. Wainwright BioConnect Conference, which will be held January 10-13, 2022. On December 20, 2021, OBSV reported about its addition to the NASDAQ Biotechnology Index with effect from December 20, 2021.

OBSV: CEO Comments

Brian O’Callaghan, CEO of the company on this occasion said that being a part of NASDAQ Biotechnology Index enabled the company to reach new customers and the company continued to grow and build its mark in the field of women reproductive health.

On December 17, 2021, OBSV reported that the Committee for Medicinal Products for Human Use of the European Medicines Agency had given encouraging opinion regarding the recommendation of the approval of linzagolix. It is in Phase 3 clinical trials. If approved, it would be a pioneer GnRH receptor adversary along with a non-hormonal selection choice.

On December 10, 2021, OBSV reported that the company’s executive management presented clinical development regarding linzagolix at the 7th Virtual Society of Endometriosis and Uterine Disorders Congress held on December 9-11, 2021. On November 22, 2021, OBSV reported that FDA had accepted its New Drug Application for linzagolix for review.

OBSV: Key Financials

On November 4, 2021, OBSV reported about its financial results for the quarter ended September 30, 2021. Some of the key updates are as follows

Net Income/Loss per Share

Basic and diluted net income for third quarter 2021 was $0.8 million, or $0.01 per share, against a net loss of $24.4 million, or $0.49 per share, for the same period of 2020.

Total Current Assets

Total current assets reported by the company for Q3 2021 were $72 million as compared to the same period of prior year when it was $56.2 million.


OBSV stock declined 27% as compared to the past six months. The current increase in the regular trading is possibly the product of the company’s latest announcement of attending Bioconnect conference. The conference will connect the company with the possible investors and stockholders of the company thus paving a way for its fruitful entry into the new year.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts




The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.

Receive Best Stock To Trade Before The Opening Bell



100% Free. Stop Anytime. No Spam